近日，诚意药业（603811）发布2025年第一次临时股东会决议公告，股东会以99%以上的票数审议通过 了2025年员工持股计划及相关制度文件。时隔一周，"2025年员工持股计划签约仪式"于浙江省温州市洞 头制造部隆重举行，总经理赵春建出席并代表公司与第一期纳入计划的200多名员工签约，"诚意药业 2025年员工持股计划"正式启动实施。 据悉，诚意药业上市以来，内外生产经营环境向好、向上，营收规模已从2021年的2.15亿元增长至7亿 元以上，利润规模超2亿元，已成为温州市最为优秀的上市公司之一。更进一步，员工持股计划指出， 为建立和完善员工、股东的利益共享机制，进一步完善公司治理水平，提高员工的凝聚力和公司竞争 力，充分调动公司中高层管理人员和广大员工的积极性与创造性，加快公司高质量发展，确保公司发展 战略和经营目标的实现，公司董事会依据《公司法》《证券法》等有关法律法规，制定了《浙江诚意药 业股份有限公司2025年员工持股计划(草案)》，并于7月13日公告了《员工持股计划管理办法》等文 件。 据相关报道，员工签约后，列入持股计划的员工纷纷开设个人账户，并做好缴款准备。赵春建表示， 《员工持股计划》实施后， ...

金融界消息 截至2025年8月19日收盘，诚意药业（603811）报收于16.82元，上涨10.01%，换手率 9.54%，成交量31.23万手，成交金额5.14亿元。 资金流向方面，今日主力资金净流入1.24亿元，占比成交额24.17%。其中，超大单净流入1.25亿元、占 成交额24.37%，大单净流出106.20万元、占成交额0.21%，中单净流出流出5593.68万元、占成交额 10.88%，小单净流出6828.50万元、占成交额13.29%。 诚意药业最新一期业绩显示，截至2025一季报，公司营业总收入1.86亿元、同比增长21.26%，归属净利 润4579.32万元，同比增长40.10%，扣非净利润4532.86万元，同比增长46.74%，流动比率1.565、速动比 率1.042、资产负债率22.38%。 天眼查商业履历信息显示，浙江诚意药业股份有限公司，成立于2001年，位于温州市，是一家以从事医 药制造业为主的企业。企业注册资本32730.432万人民币，实缴资本32730.432万人民币。公司法定代表 人为赵春建。 通过天眼查大数据分析，浙江诚意药业股份有限公司共对外投资了8家企业，参与招投标 ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

Group 1 - The company announced the resignation of Vice General Manager Ren Bingjun due to reaching the statutory retirement age [2][3] - Ren Bingjun's resignation will take effect upon delivery of the resignation report to the board of directors, and he will continue to hold other positions within the company after his departure [3] - As of the announcement date, Ren Bingjun holds 5,762,455 shares of the company, and his resignation is not expected to impact the company's normal operations [3][4] Group 2 - The company expresses sincere gratitude for Ren Bingjun's contributions and efforts during his tenure as Vice General Manager [4] - The announcement was made by the board of directors on August 18, 2025 [5]

证券日报网讯8月18日晚间，诚意药业（603811）发布公告称，公司董事会收到公司副总经理任秉钧先 生的书面辞职报告。任秉钧先生因达到法定退休年龄，辞去公司副总经理职务。 ...

Group 1 - Company Chengyi Pharmaceutical announced on August 18 that Mr. Ren Bingjun has resigned from the position of Deputy General Manager due to reaching the statutory retirement age [2] - The resignation report becomes effective upon delivery to the board of directors, in accordance with relevant regulations [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603811 证券简称：诚意药业 公告编号：2025-043 浙江诚意药业股份有限公司 浙江诚意药业股份有限公司（简称"公司"）董事会收到公司副总经理任秉 钧先生的书面辞职报告。任秉钧先生因达到法定退休年龄，辞去公司副总经理职 务。根据相关规定，上述辞职报告自送达董事会时生效。 关于公司高级管理人员退休离任的公告 根据《中华人民共和国公司法》和《公司章程》等相关规定，任秉钧先生的 辞职报告自送达公司董事会之日起生效，任秉钧先生离任后将继续在公司担任其 他职务。截至本公告披露日，任秉钧先生持有公司股票 5,762,455 股。上述事项 对公司正常的生产经营不会产生影响。 公司对任秉钧先生在担任公司副总经理期间做出的贡献和努力表示衷心的 感谢！ 特此公告。 浙江诚意药业股份有限公司董事会 2025 年 8 月 18 日 一、董事/高级管理人员离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是 ...

诚意药业8月18日公告，公司董事会收到副总经理任秉钧的书面辞职报告，任秉钧因达到法定退休年 龄，辞去公司副总经理职务。根据相关规定，上述辞职报告自送达董事会时生效。任秉钧离任后将继续 在公司担任高级技术顾问（退休返聘）。 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock market activity of Chengyi Pharmaceutical Co., Ltd. as of August 14, 2025, showing a decline in stock price and significant net outflow of funds [1] - Chengyi Pharmaceutical reported total revenue of 186 million yuan for Q1 2025, representing a year-on-year growth of 21.26%, and a net profit attributable to shareholders of 45.79 million yuan, up 40.10% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 1.565 and a quick ratio of 1.042, alongside a low debt-to-asset ratio of 22.38% [1] Group 2 - Chengyi Pharmaceutical has made investments in 8 companies and participated in 3,615 bidding projects, indicating active engagement in business expansion [2] - The company holds 78 trademark registrations and 43 patents, showcasing its commitment to intellectual property and innovation [2] - Additionally, Chengyi Pharmaceutical possesses 283 administrative licenses, reflecting its compliance and operational capabilities within the pharmaceutical industry [2]

Group 1 - The stock price of Chengyi Pharmaceutical is reported at 15.65 yuan as of August 12, 2025, reflecting a decrease of 0.33 yuan from the previous trading day [1] - The opening price for the day was 16.16 yuan, with a highest point of 16.45 yuan and a lowest point of 15.26 yuan, resulting in an intraday volatility of 7.45% [1] - The trading volume reached 548,445 hands, with a total transaction amount of 870 million yuan [1] Group 2 - Chengyi Pharmaceutical primarily engages in chemical pharmaceutical business, with products covering various therapeutic areas including anti-infection drugs, anti-tumor drugs, and cardiovascular drugs [1] - The company is headquartered in Zhejiang Province and holds a certain market position in the pharmaceutical manufacturing sector [1] Group 3 - On August 12, the net outflow of main funds was 39.1563 million yuan, with a cumulative net outflow of 90.5487 million yuan over the past five trading days [1] - The stock experienced rapid fluctuations during the trading session, with a quick 2% drop at 9:37 AM followed by a 2% rebound at 9:50 AM, indicating active market trading [1]